



Mary B. Matterer
302.888.6960
mmatterer@morrisjames.com

BY FACSIMILE AND E-FILING

The Honorable Robert B. Kugler
United States District Judge
District of New Jersey
Mitchell H. Cohen Building & U.S. Courthouse
4th & Cooper Streets, Room 1050
Camden, NJ 08101

Re: *Sciele Pharma, Inc., et al. v. Lupin Ltd., et al.*,
C.A. No. 09-037 (RBK) (JS)

Shionogi Pharma, Inc., et al. v. Mylan Inc, et al.,
C.A. No. 10-135 (RBK) (JS)

Your Honor:

This firm along with McGuireWoods LLP represents Mylan Inc. and Mylan Pharmaceuticals Inc. (collectively, "Mylan") in the above-referenced, consolidated actions. We write to request that Your Honor place the actions on the Court's March 2013 trial calendar, if not sooner.

The plaintiffs and Mylan's co-defendants, Lupin Pharmaceuticals Inc. and Lupin Ltd. (collectively, "Lupin"), today submitted to the Court a stipulation (D.I. 484) requesting that the Court modify the case schedule to extend the remaining deadlines. As requested, the modified schedule would have dispositive motions and Daubert motions due January 31, 2013. A copy of the stipulation is attached to this letter as Exhibit A.

As indicated in Footnote 1 of the stipulation, Mylan did not agree with the other parties that an extension of the duration requested was necessary, but, in the interest of limiting issues to be resolved by the Court, agreed nevertheless not to object to the requested extension. And, to be clear, Mylan is not here objecting. Mylan is cognizant of its obligation under the Hatch-Waxman Act to expedite these actions, however, and it is in the spirit of adhering to this obligation that Mylan writes the Court. *See Eli Lilly & Co. v. Medtronic, Inc.*, 496 U.S. 661, 676 (1990) (acknowledging that one of the key objectives of the Hatch-Waxman Act was to "substantially shorten the time and effort needed to obtain marketing approval" to "enable new drugs to be marketed more cheaply and quickly").

Notwithstanding the current, requested extension, Mylan believes discovery in these actions reasonably could be completed in time for a 2012 trial. Indeed, one of the schedule modifications proposed (and later abandoned) by Lupin would have allowed for the possibility of

The Honorable Robert B. Kugler
June 29, 2012
Page 2

a 2012 trial. That obviously is not the case with the newly requested schedule modification. Regardless, Mylan believes that, even under the newly requested schedule modification, assuming it is adopted by the Court, the actions could be tried in early 2013. Notably, the action to which Mylan is a party has been pending since February 2010. Lupin's action has been pending more than a full year longer.

The parties have met and conferred on this issue but could not reach agreement. Initially, the other parties were unwilling to request to be placed on the trial calendar at all. Plaintiff Shionogi Pharma Inc. ultimately proposed seeking a June 2013 trial date (and, it appears the other parties were in agreement), but Mylan does not believe there is any reason these cases should haunt the Court's docket for another full year. Therefore, Mylan respectfully requests that, assuming the Court adopts the stipulated schedule modification, Your Honor place these actions on the trial calendar for no later than March 2013.

We would be happy to answer any questions the Court may have. We thank the Court for its consideration of this matter.

Respectfully,

/s/ Mary B. Matterer

Mary B. Matterer (Bar I.D. No. 2696)
mmatterer@morrisjames.com

cc: The Honorable Joel Schneider (via facsimile)
Counsel of record (via email)

EXHIBIT A

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

SCIELE PHARMA, INC. <i>et al.</i> ,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 09-037 (RBK) (JS)
)	(CONSOLIDATED)
LUPIN LTD., <i>et al.</i> ,)	
)	
Defendants.)	
<hr style="width: 45%; margin-left: 0;"/>		
SHIONOGI, INC., <i>et al.</i> ,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 10-135 (RBK) (JS)
)	
MYLAN, INC., <i>et al.</i> ,)	
)	
Defendants.)	

**JOINT STIPULATION REGARDING
AMENDED SCHEDULING ORDER**

IT IS HEREBY STIPULATED AND AGREED, subject to the approval of the Court, by and among the undersigned counsel for Plaintiffs Sciele Pharma, Inc., n/k/a Shionogi, Inc., Andrx Corporation, Andrx Pharmaceuticals, Inc. (n/k/a Watson Laboratories, Inc. – Florida), Andrx Pharmaceuticals, L.L.C., Andrx Pharmaceuticals (NJ), Inc., Andrx EU, Ltd., and Andrx Labs, L.L.C., and Defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc., that the deadlines in the Amended Scheduling Order (D.I. 393) shall be revised as follows:¹

1. Pretrial factual discovery is hereby extended to **August 31, 2012**.²

¹ Although Defendants Mylan Inc. and Mylan Pharmaceuticals Inc. (collectively, “Mylan”) agree that a modification to the schedule is warranted, they do not agree that an extension of the requested duration is necessary. We are authorized to represent that Mylan will not formally oppose the requested extension and agrees to be bound by this stipulation.

² Lupin will work together with the other parties in an attempt to meet the proposed deadlines, but Lupin has concerns that an additional extension may be needed.

2. All parties with the affirmative burden of proof on an issue shall serve expert reports and expert disclosures pursuant to FED. R. CIV. P. 26(a)(2) by **October 2, 2012**. Responsive expert reports and expert disclosures pursuant to FED. R. CIV. P. 26(a)(2) shall be served by **November 9, 2012**. Each such report shall be accompanied by the curriculum vitae of the proposed expert witness. No expert opinion testimony shall be admitted at trial with respect to any witness for whom this procedure has not been timely followed. Depositions of proposed expert witnesses shall be concluded by **December 31, 2012**.

3. Dispositive and Daubert motions shall be filed with the Clerk of the Court no later than **January 31, 2013**, in accordance with the applicable Federal and Local Rules.

June 29, 2012

RICHARDS, LAYTON & FINGER P.A.

/s/ Jason J. Rawnsley
Frederick L. Cottrell, III (#2555)
Steven J. Fineman (#4025)
Jason J. Rawnsley (#5379)
One Rodney Square
P.O. Box 551
Wilmington, DE 19899
(302) 651-7700
cottrell@rlf.com
fineman@rlf.com
rawnsley@rlf.com

*Attorneys for Andrx Corporation, Andrx
Pharmaceuticals, Inc. (n/k/a Watson
Laboratories, Inc.-florida), Andrx
Pharmaceuticals, L.L.C., Andrx Laboratories
(NJ), Inc., Andrx EU Ltd. and Andrx Labs,
L.L.C.*

OF COUNSEL:

Gary E. Hood
POL SINELLI SHUGHART PC
161 North Clark Street, Suite 4200

BAYARD, P.A.

/s/ Stephen B. Brauerman
Richard D. Kirk (#922)
Stephen B. Brauerman (#4952)
222 Delaware Avenue, Suite 900
Wilmington, DE 19801
(302) 655-5000
rkirk@bayardlaw.com
sbrauerman@bayardlaw.com

*Attorneys for Lupin Ltd. and Lupin
Pharmaceuticals, Inc.*

OF COUNSEL:

Douglass C. Hochstetler
KELLEY DRYE & WARREN LLP
333 West Wacker Drive, 26th Floor
Chicago, IL 60606

Beth D. Jacob
Clifford Katz
KELLEY DRYE & WARREN LLP
101 Park Avenue
New York, NY 10178

Chicago, IL 60601-3316

Robyn H. Ast
POL SINELLI SHUGHART PC
100 South Fourth Street, Suite 1000
St. Louis, MO 63102

Karen A. Confoy
Erica A. Helms
STERN & WEINROTH PC
50 West State Street, Suite 1400
Trenton, NJ 08607

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Jennifer Ying

Jack B. Blumenfeld (#1014)
Karen Jacobs Loudon (#2881)
Julia Heaney (#3052)
Jennifer Ying (#5550)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899-1347
(302) 658-9200
jblumenfeld@mnat.com
kloudon@mnat.com
jheaney@mnat.com
jying@mnat.com

Attorneys for Sciele Pharma, Inc.

OF COUNSEL:

David A. Manspeizer
David B. Bassett
Christopher R. Noyes
David M. Burkoff
Peter Shen
WILMER CUTLER PICKERING HALE AND DORR
LLP
399 Park Avenue
New York, NY 10022

Liza M. Walsh
Rukhsanah Lighari
Patrick J. Murphy
CONNELL FOLEY LLP
85 Livingston Avenue
Roseland, NJ 07068

IT IS SO ORDERED THIS ____ day of _____, 2012.

The Honorable Joel Schneider
United States Magistrate Judge